中草药治疗原发性脑出血疗效与安全性的系统评价
该系统评价纳入45项随机对照试验共4517例急性原发性脑出血患者,评估中草药辅助治疗的效果与安全性。结果显示中草药辅助治疗可改善依赖程度、神经功能缺损、血肿体积、临床有效率及血肿周围水肿体积(均P<0.05),但对死亡率改善无统计学意义(P>0.05)。不良事件在16项研究中报告,试验组频率为70/972,对照组为48/944。
要点
- 中草药辅助治疗可改善脑出血患者依赖程度和神经功能缺损。
- 中草药辅助治疗对死亡率改善无统计学意义(P>0.05)。
- 不良事件报告不充分,29项研究未提及安全性数据。
核心结论
- 中草药辅助治疗对急性原发性脑出血的依赖程度、神经功能缺损、血肿体积、临床有效率及血肿周围水肿体积有改善作用(均P<0.05)。
- 中草药辅助治疗对脑出血患者死亡率改善无统计学意义(P>0.05)。
- 中草药治疗总体显示安全性,但不良事件报告不充分。
研究设计与样本
- 纳入45项随机对照试验,共4517例个体。
- 仅纳入根据Cochrane偏倚风险工具至少4个领域评为「是」的研究。
- 使用Review Manager 5.3软件进行数据分析,P<0.05为统计学显著。
主要发现
- 与单用中草药或安慰剂相比,中草药辅助治疗可改善依赖程度(P<0.05)。
- 中草药辅助治疗可改善神经功能缺损(P<0.05)。
- 中草药辅助治疗可缩小血肿体积(P<0.05)。
- 中草药辅助治疗可提高临床有效率(P<0.05)。
- 中草药辅助治疗可缩小血肿周围水肿体积(P<0.05)。
关键数值与推荐
- 死亡率改善无统计学意义(P>0.05)。
- 16项研究报告不良事件,试验组频率为70/972,对照组为48/944。
- 29项研究未提及不良事件。
临床怎么用
- 中草药可作为急性原发性脑出血的辅助治疗以改善依赖程度和神经功能缺损。
- 使用中草药辅助治疗时需关注不良事件,尽管现有报告不充分。
- 不推荐仅依赖中草药来改善脑出血患者死亡率。
局限性
- 仅纳入Cochrane偏倚风险工具至少4个领域为「是」的研究,可能排除部分证据。
- 29项研究未报告不良事件,安全性数据不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Primary intracerebral hemorrhage (ICH) is the most harmful subtype of stroke, but there have yet been no specific proven therapies. Chinese herbal medicine (CHM) has been used for ICH for more than a thousand years; however, currently it is still lacking of available evidence. The objective of this study is to assess the current available evidence of CHM for acute ICH according to randomized controlled trials. Methods: Eight databases were searched from the year of their respective inception to November 2017. Only the studies that assessed at least four domains with "yes" according to the Cochrane risk of bias tool were selected for analysis. All the data were analyzed by using Review Manager 5.3 software. P < 0.05 was considered to be statistically significant. Results: Forty-five studies with 4,517 individuals were identified. CHM paratherapy can improve dependency, neurological function deficit, volume of hematoma, clinical effective rate, and volume of perihematomal edema compared with CHM alone or placebo (all P < 0.05). By contrast, it was not significant for improving the mortality rate of ICH patients (P > 0.05). In addition, adverse events were reported in 16 studies, whereas 29 studies did not mention it. The frequency of adverse events was 70/972 in the trial group and 48/944 in the control group. Conclusion: The present study provided supportive evidence of CHM for improving dependency of ICH and showed generally safety; however, there is still lack of evidence for improving mortality rate, and it opens for further study.
引用
- Wang HL, Zeng H, Xu MB, et al. Efficacy and Safety of Chinese Herbal Medicine for Primary Intracerebral Hemorrhage: A Systematic Review of Randomized Controlled Trials. Front Pharmacol. 2019. PMID: 31649531. doi:10.3389/fphar.2019.01139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。